Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Study acronym: MAPKeeper 301
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 57 → 63 locations
  2. Study sites: 57 to 59
  3. Trial sites expanded: 51 → 57 locations
    • Study sites revised (57)
  4. Study sites: 51 to 57
  5. Trial sites expanded: 48 → 51 locations
  6. Trial sites expanded: 45 → 48 locations
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 5 entries
  7. Study sites: 43 to 45v22
  8. Site contacts updated at 1 of 43 sitesv21
  9. Study sites: 41 to 43v20
  10. Trial sites expanded: 38 → 41 locationsv19
  11. Trial sites expanded: 35 → 38 locationsv18
  12. Study sites: 33 to 35v17
  13. Study sites: 31 to 33
    • Start date changed from estimate of Jun 2026 to Jun 5, 2026
    v16
  14. Trial sites expanded: 25 → 30 locationsv15
  15. Study sites: 25 to 30v14
  16. Study sites: 23 to 25v13
  17. Study sites: 22 to 23v12
  18. Trial sites expanded: 19 → 22 locationsv11
  19. Trial sites expanded: 16 → 19 locationsv10
  20. Study sites: 17 to 16v9
  21. Trial sites expanded: 13 → 17 locationsv8
  22. Trial sites expanded: 10 → 13 locations
    • Eligibility criteria shortened, about 1 word
    v7
  23. Trial sites expanded: 6 → 10 locationsv6
  24. Study sites: 6 to 10
    • Start date: May 2026 to Jun 2026
    v5
  25. Site contacts updated at 2 of 6 sitesv4
  26. Trial sites expanded: 3 → 6 locationsv3
  27. Secondary endpoints: details revised at 1 of 5 entriesv2
  28. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Trial Details
NCT Number NCT07562152
Lead Sponsor Immuneering Corporation
Conditions
(from sponsor)		 Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma
Related terms Neoplasm Metastasis, Pancreatic Neoplasms
Enrollment 510 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov